GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis

 
• By Cathy Kelly

GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research

More from Archive

More from Pink Sheet